Panacea Biotec Secures ₹20.79 Crore Vaccine Supply Contract from CMSS
Panacea Biotec received a Letter of Award from Central Medical Services Society for supplying Td Vaccine. The contract value is ₹20.79 Crore. Supplies will occur between September/October 2026 and November/December 2028.
The contract value of ₹20.79 Crore is significant, but it will be executed over a period of approximately two years, suggesting a moderate impact on the company's overall financials.
The company has received a new order, which is generally a positive development indicating business growth and revenue.
Panacea Biotec Limited has announced the receipt of a Letter of Award (LOA) dated April 10, 2026, from the Central Medical Services Society (CMSS), an entity under the Ministry of Health and Family Welfare, Government of India.
The award pertains to the supply of Diphtheria and Tetanus Vaccine (Absorbed) for Adults and Adolescents IP, commonly known as Td Vaccine.
The supply will be executed in several tranches to CMSS, commencing from September/October 2026 and concluding by November/December 2028. The total value of this contract aggregates to ₹20.79 Crore.
This contract is with a domestic entity, and Panacea Biotec Limited confirms that neither the promoter, promoter group, nor any group companies have any interest in CMSS, and the transaction does not fall under related party transactions.
What to do with a filing like this
Panacea Biotec Limited filed this with the NSE as a statutory disclosure, categorised under new orders. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Panacea Biotec Limited. Read the original for the full detail.